Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 2/20 | 0.52 |
| ▸ | NPC1 | O15118 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.51 |
| ▸ | PKM | P14618 | 1/20 | 0.51 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 4/20 | 0.49 |
| ▸ | LMNA | P02545 | 2/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 3/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.48 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.45 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.45 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ammonia Solution, Strong SCHEMBL29063683 | 0.98 | RAB9A (0.51) | RAB9ANPC1ALDH1A1PKMRXFP1 | |
| SCHEMBL588563 | 0.87 | RAB9A (0.62) | RAB9ANPC1ALDH1A1PKMRXFP1 | |
| Ammonia Solution, Strong SCHEMBL20358007 | 0.86 | RAB9A (0.60) | RAB9ANPC1ALDH1A1PKMRXFP1 | |
| SCHEMBL20982526 | 0.84 | RAB9A (0.72) | RAB9ANPC1ALDH1A1PKMRXFP1 | |
| SCHEMBL17488171 | 0.83 | ALDH1A1 (0.51) | RAB9AALDH1A1PKMRXFP1MAPT | |
| SCHEMBL3834332 | 0.83 | ALDH1A1 (0.50) | RAB9ANPC1ALDH1A1PKMRXFP1 | |
| SCHEMBL29921905 | 0.80 | MAPT (0.49) | RAB9ANPC1ALDH1A1PKMRXFP1 | |
| SCHEMBL3969164 | 0.80 | MEN1 (0.50) | RAB9ANPC1ALDH1A1MAPTLMNA | |
| SCHEMBL7261471 | 0.80 | CYP1A2 (0.56) | RAB9ANPC1ALDH1A1MAPTLMNA | |
| SCHEMBL20982760 | 0.80 | ALDH1A1 (0.69) | RAB9ANPC1ALDH1A1PKMRXFP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170197920-A1 | FLUOROALKYLATING AGENT | IHARA CHEMICAL INDUSTRY CO., LTD. (JP) | 2017-07-13 | — | — | US | disclosed |
| US-20170197920-A1 | FLUOROALKYLATING AGENT | IHARA CHEMICAL INDUSTRY CO., LTD. (JP) | 2017-07-13 | — | — | US | disclosed |
| US-8735432-B2 | N-(Heteroaryl)-1-heteroarylalky1-1H-indole-2-carboxamide derivatives, preparation and therapeutic use thereof | SANOFI (FR) | 2014-05-27 | — | — | US | disclosed |
| US-20130046095-A1 | N-(Heteroaryl)-1-heteroarylalkyl-1H-indole-2-carboxamide derivatives, preparation and therapeutic use thereof | DUBOIS LAURENT (FR) | 2013-02-21 | — | — | US | disclosed |
| US-8318775-B2 | N-(heteroaryl)-1-heteroarylalkyl-1H-indole-2-carboxamide derivatives, preparation and therapeutic use thereof | SANOFI (FR) | 2012-11-27 | — | — | US | disclosed |
| EP-1944305-B1 | Quinoline derivatives as phosphodiesterase inhibitors | GLAXO GROUP LTD (GB) | 2011-10-19 | — | — | EP | disclosed |
| US-20100222368-A1 | N-(Heteroaryl)-1-heteroarylalkyl-1H-indole-2-carboxamide derivatives, preparation and therapeutic use thereof | SANOFI-AVENTIS (FR) | 2010-09-02 | — | — | US | disclosed |
| US-7745467-B2 | N-(heteroaryl)-1-heteroarylalkyl-1H-indole-2-carboxamide derivatives, preparation and therapeutic use thereof | SANOFI-AVENTIS (FR) | 2010-06-29 | — | — | US | disclosed |
| US-20090312325-A1 | Quinoline Derivatives As Phosphodiesterase Inhibitors | BALDWIN IAN ROBERT | 2009-12-17 | — | — | US | disclosed |
| US-7572915-B2 | 4-[(3-methylphenyl)amino]-6-(methylsulfonyl)-3-quinolinecarboxamide; asthma, COPD, allergic rhinitis, or rheumatoid arthritis in a human | GLAXO GROUP LIMITED (GB) | 2009-08-11 | — | — | US | disclosed |
| EP-1944305-A1 | Quinoline derivatives as phosphodiesterase inhibitors | GLAXO GROUP LIMITED (GB) | 2008-07-16 | — | — | EP | disclosed |
| US-20080146646-A1 | N-(Heteroaryl)-1-heteroarylalkyl-1H-indole-2-carboxamide derivatives, preparation and therapeutic use thereof | SANOFI-AVENTIS (FR) | 2008-06-19 | — | — | US | disclosed |
| EP-1633748-B1 | QUINOLINE DERIVATIVES AS PHOSPHODIESTERASE INHIBITORS | GLAXO GROUP LTD (GB) | 2008-03-05 | — | — | EP | disclosed |
| US-20070142373-A1 | Quinoline derivatives as phosphodiesterase inhibitors | GLAXO GROUP LIMITED (GB) | 2007-06-21 | — | — | US | disclosed |
| US-20070049570-A1 | Quinoline derivatives as phosphodiesterase inhibitors | DEAN ANTHONY W | 2007-03-01 | — | — | US | disclosed |
| US-20060178416-A1 | Quinoline derivatives as phosphodiesterase inhibitors | BARKER MICHAEL D | 2006-08-10 | — | — | US | disclosed |
| US-6828116-B1 | Energy transfer assay method and reagent | AMERSHAM BIOSCIENCES UK LIMITED (GB) | 2004-12-07 | — | — | US | disclosed |
| EP-1086179-B1 | ENERGY TRANSFER ASSAY METHOD AND REAGENT | AMERSHAM BIOSCIENCES UK LTD (GB) | 2003-04-23 | — | — | EP | disclosed |
| EP-1086179-A1 | ENERGY TRANSFER ASSAY METHOD AND REAGENT | Amersham Pharmacia Biotech UK Ltd. (GB) | 2001-03-28 | — | — | EP | disclosed |
| WO-1999064519-A1 | ENERGY TRANSFER ASSAY METHOD AND REAGENT | AMERSHAM BIOSCIENCES CORP (GB) | 1999-12-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100222368-A1 | N-(Heteroaryl)-1-heteroarylalkyl-1H-indole-2-carboxamide derivatives, preparation and therapeutic use thereof | IDO1, IDO2, CNR2 | RAB9A 2329/4885NPC1 230/4885ALDH1A1 862/4885 |
| US-20060178416-A1 | Quinoline derivatives as phosphodiesterase inhibitors | PDE3B, PDE4B, PDE4A | RAB9A 211/4885NPC1 4158/4885ALDH1A1 623/4885 |
| US-20170197920-A1 | FLUOROALKYLATING AGENT | AFF1, AFF4, AFF2 | RAB9A 975/4885NPC1 1354/4885ALDH1A1 2072/4885 |
| US-20090312325-A1 | Quinoline Derivatives As Phosphodiesterase Inhibitors | PDE3B, PDE4B, PDE4A | RAB9A 211/4885NPC1 4158/4885ALDH1A1 623/4885 |
| US-20130046095-A1 | N-(Heteroaryl)-1-heteroarylalkyl-1H-indole-2-carboxamide derivatives, preparation and therapeutic use thereof | IDO1, IDO2, CNR2 | RAB9A 2329/4885NPC1 230/4885ALDH1A1 862/4885 |
| US-20070049570-A1 | Quinoline derivatives as phosphodiesterase inhibitors | PDE3B, PDE4B, PDE4A | RAB9A 211/4885NPC1 4158/4885ALDH1A1 623/4885 |
| US-20080146646-A1 | N-(Heteroaryl)-1-heteroarylalkyl-1H-indole-2-carboxamide derivatives, preparation and therapeutic use thereof | IDO1, IDO2, CNR2 | RAB9A 2329/4885NPC1 230/4885ALDH1A1 862/4885 |
| US-20070142373-A1 | Quinoline derivatives as phosphodiesterase inhibitors | PDE3B, PDE4B, PDE4A | RAB9A 211/4885NPC1 4158/4885ALDH1A1 623/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.